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osting by EAbstract Traditional diets of people living in the Mediterranean basin are, among other compo-
nents, very rich in extra-virgin olive oil, the most typical source of visible fat. Olive is a priceless
source of monounsaturated and di-unsaturated fatty acids, polyphenolic antioxidants and vitamins.
Oleuropein is the main glycoside in olives and is responsible for the bitter taste of immature and
unprocessed olives. Chemically, oleuropein is the ester of elenolic acid and 3,4-dihydroxyphenyl eth-
anol, which possesses beneﬁcial effects on human health, such as antioxidant, antiatherogenic, anti-
cancer, anti-inﬂammatory and antimicrobial properties. The phenolic fraction extracted from the
leaves of the olive tree, which contains signiﬁcant amounts of oleuropein, prevents lipoprotein oxi-
dation. In addition, oleuropein has shown cardioprotective effect against acute adriamycin cardio-
toxicity and an anti-ischemic and hypolipidemic activities. Recently, oleuropein has shown
neuroprotection by forming a non-covalent complex with the Ab peptide, which is a key hallmark
of several degenerative diseases like Alzheimer and Parkinson. Thus, a large mass of research has
been accumulating in the area of olive oil, in the attempt to provide evidence for the health beneﬁts
of olive oil consumption and to scientiﬁcally support the widespread adoption of traditional Med-
iterranean diet as a model of healthy eating. These results provide a molecular basis for some of the
beneﬁts potentially coming from oleuropein consumption and pave the way to further studies on
the possible pharmacological use of oleuropein to prevent or to slow down the cardiovascular
and neurodegenerative diseases.
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A relation between diet and heart health had been shown by
experimental studies over 100 years ago. However, it was not
until the epidemic rise of cardiovascular diseases in many
industrialized countries during the middle of the 20th century
that the identiﬁcation of risk factors and the need to put in
place preventive measures became crucial. The ﬁeld of epide-
miology provided the ﬁrst leads to explain such risk factors.
Epidemiology studies demonstrated that dietary saturated fat
intake was signiﬁcantly associated with serum cholesterol
and the risk of coronary heart disease, and that serum choles-
terol relates to coronary heart disease risk. The outcome of
Keys et al. (1986) study brought up the concept of the cardio-
protective properties of the dietary habits of Mediterranean
populations, which appeared to have as the most common ele-
ment the consumption of virgin olive oil. For the last few dec-
ades, several population studies aimed to solidify the initial
observation from the Seven Country Study and demonstrate
the relevance of virgin olive oil as a key cardioprotective com-
ponent of the Mediterranean diet (Trichopoulou et al., 2003).
Ageing also represents a great concern in developed coun-
tries because of the increasing number of persons reaching ad-
vanced age and the number of related pathologies, such as
Alzheimer’s disease, vascular dementia, Morbus Parkinson,
diabetes or cancer. A typical Mediterranean diet, the high
monounsaturated fat energy intake appeared to be associated
with a reduced risk of age-related cognitive decline (Solfrizzi
et al., 1999). This effect could be related to the role of mono-
unsaturated fatty acids in maintaining the structural integrity
of neuronal membranes (Solfrizzi et al., 1999; Panza et al.,
2004). Moreover, high intake of monounsaturated fat showed
protective effect against Alzheimer’s disease, whereas intake of
saturated or trans-unsaturated fats leads to detrimental (Panza
et al., 2004).
Several experimental data supported that virgin olive oil
contains a higher concentration of three phenolic antioxidants
classes, simple phenols, secoiridoids and lignans, and squalenethan reﬁned virgin oil and seed oils. For these reasons, in the
Mediterranean region, where olive oil is an essential constitu-
ent of the diet, there is a lower incidence of cancer and heart
disease (Gerber, 1994; Keys, 1995).
Oleuropein is the major bioactive compound of Olea euro-
paea, widely known as the olive tree and present in high
amount in unprocessed olive fruit and leaves. During matura-
tion of fruit or as a results of olive processing (such as oil pro-
duction), chemical and enzyme reactions occur which reduce
the concentration of oleuropein and raise the concentration
of hydroxytyrosol which is the principal degradation product
of oleuropein. The oleuropein molecule consists of three struc-
tural subunits: a polyphenol, namely 4-(2-hydroxyethyl) ben-
zene-1,2-diol which is also known as hydroxytyrosol (HT), a
secoiridoid called elenolic acid and a glucose molecule (Fig. 1).
Oleuropein possesses beneﬁcial pharmacological effects
such as cardiprotective effect antioxidant (Andreadou et al.,
2006), anti-inﬂammatory (Visioli et al., 1998), inhibition of
platelet aggregation (Petroni et al., 1995), anti-atherogenic
(Manna et al., 2004; Visioli and Galli, 2001) activity, anti-can-
cer (Hamdi and Castellon, 2005), anti-microbial properties
(Bisignano et al., 1999) and neuroprotective effect (Bazoti
et al., 2006). This review summarizes the health beneﬁts of
oleuropein from virgin olive oil and leaf extract and its cardi-
protective and neuroprotective effect as tools for future drug
research.
2. Occurrence
Phenolic compounds are found in all parts of the plant but
their nature and concentration varies greatly between the var-
ious tissues. In O. europaea, oleuropein, demethyloleuropein,
ligstroside and oleoside represent the predominant phenolic
oleosides (Soler-Rivas et al., 2000), whereas verbascoside
(Ryan et al., 1999) is the main hydroxycinnamic derivative of
olive fruit (Servili et al., 1999). Oleuropein is generally the most
prominent phenolic compound in olive cultivars and may
reach concentrations of up to 140 mg g1 on a dry matter basis
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Figure 1 Molecular structure of oleuropein molecule.
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matter in the leaves (Le Tutour and Guedon, 1992).
Various methods have been developed for qualitative and
quantitative occurrence of phenolic and secoiridoid com-
pounds analysis, from the most simple techniques to the more
sophisticated such as TLC (Capasso et al., 1992), reversed
phase HPLC (Ficarra et al., 1991; De Laurentis et al., 1997),
GC–MS, FAMS or TMS (Baracco et al., 1995). In the fruits,
phenyl acids, ﬂavonoids and secoiridoids have been reported,
the phenolic compounds representing 1–3% (w/v) Brenes
et al., 1993. In the leaves, 19% (w/w) is oleuropein and 1.8%
(w/w) ﬂavonoids, of which 0.8% is luteolin 7-glucoside (Le
Tutour and Guedon, 1992).
Oleuropein occurs not only in the Olea genus but also in
many other genera belonging to the Oleaceae family and has
been described in Fraximus excelsior, Fraximus angustifolia,
Fraximus chinensis, Syringa josikaea, Syringa vulgaris, Phily-
rea latifolia, Ligustrum ovalifolium, Ligustrum vulgare and
many others (Soler-Rivas et al., 2000).
3. Chemistry, synthesis and fate of oleuropein
3.1. Chemistry and synthesis
In olive, two main groups of compounds are present: fats, as
glycerides and lipids, and phenols and related substances.
Oleuropein is the ﬁrst secoiridoid that structure was recognised
in 1958–1965, but only several years later it was classiﬁed as
secoiridoid, when this class of monoterpenoids was constituted
(Fig. 2).
Oleuropein structure was determined by Panizzi et al.
(1958) and Panizzi and Scarpati (1960) from fresh leaves in
amount from 1.5% to 2%. Only the absolute conﬁgurations
of C-l and C-5 remained undetermined, as the cis/trans con-
ﬁguration of C-8/C-9 double bond. Inouye et al. (1970) deter-mined some years later (Panza et al., 2004), the absolute
conﬁguration of chiral centres of the secoiridoid oleuropein
A, relating A to the iridoid asperuloside B shown in Fig. 3.
Bisdeoxy-acetyl asperuloside C, prepared by hydrogenolysis
from asperuloside B, was opened by a series of oxidative
steps to the two secoiridoid dimethyl esters D1 and D2, hav-
ing racemic C-8 centre with hydroxyl in both R (D1) and S
(D2) conﬁgurations. Dehydration of these two secondary
alcohols afforded two possible oleﬁns: S-alcohol D2 afforded
the E-oleﬁn E2, while R alcohol D1 gave the Z-oleﬁn E1
shown in Fig. 3.
A simple work up on oleuropein A, transesteriﬁcation with
methanol of ester function at C-7 afforded the E-oleﬁn E2, so
demonstrating the absolute conﬁguration of the C-8/C-9 dou-
ble bond, as well as all chiral centres of oleuropein A. A similar
approach was used for the partial synthesis of oleuropein A
(Bianco et al., 1992) that was depicted in Fig. 4.
The chiral starting product was a glucosidic iridoid, the bis-
deoxy-asperuloside F. The partial synthesis starts with the pro-
tection of compound F with benzyl groups that can easily be
eliminated at the end of the synthesis in mild hydrogenolytic
conditions that do not interfere with ester functions of oleu-
ropein. After protection, compound F is osmilated to diol G.
This last compound was selectively oxidized at the vicinal diol
function with sodium periodate and successively with Jones’s
reagent, affording the desired acid H. Direct esteriﬁcation of
compound H with dioxy-phenyl-ethanol I, having phenolic
functions protected with benzyl moieties, gave the key interme-
diate secoiridoid J. The last step of the synthesis is the stereo-
selective reduction of J that afforded the alcohol K as a single
product, with the desired (S) absolute conﬁguration at C-8 cen-
tre. The compound K was then dehydrated, giving the C-8/C-9
double bond with the correct conﬁguration. The ﬁnal remov-
ing of the protecting benzyl groups by hydrogenolysis afforded
the oleuropein A.
Oleuropein A has been a recognised chemo-taxonomic mar-
ker of O. europaea; however its presence in olives is attributed
to the ripening stage of fruits. The experimental data were
achieved for some Spanish, Portuguese and Italian cultivars,
which were examined in different stages of ripening (green,
cherry and black) (Bianco and Uccella, 2000; Bastoni et al.,
2001). These data conﬁrmed the previously obtained results
(Donaire et al., 1975; Amiot et al., 1989), with a decrease of
oleuropein A during olive maturation and a contemporary
increase of oleuropein derivatives.
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114 S.H. Omar3.2. Biosynthesis
The biosynthesis of oleuropein in the Oleaceae proceeds via a
branching in the mevalonic acid pathway from the secondary
metabolism resulting in the formation of oleosides (Damtoft
et al., 1992). From these compounds secoiridoids are derived
(Damtoft et al., 1993). The biosynthesis of oleosides is similar
to that of secologanin-derived secoiridoids in Gentianales and
Cornales. In these the carbon skeleton is derived from meva-
lonic acid. Geraniol, 10-hydroxygeranoil as well as 10-hydrox-
ynerol and iridoidal are known to be precursors of loganin.
Later deoxyloganic acid, 7-epiloganic acid and loganic acid
are incorporated into ligustroside, a direct precursor of oleu-
ropein, via 7-ketologanic acid as intermediate. The sequences
of the steps between deoxyloganic acid and 7-ketologanin
may differ with plant species and time of year (Damtoft
et al., 1993). In O. europaea both possible epoxides of secolog-
anin and secoxyloganin could be the precursors for oleuropein
(Damtoft et al., 1995). A plausible biosynthetic route fromdeoxyloganic acid, 7-epiloganic acid, 7-ketologanic acid, 8-epi-
kingisidic acid, oleoside 11-methyl ester, 7-b-1-D-glucopyrano-
syl 11-methyl oleoside and ligustroside to oleuropein was
proposed by Damtoft et al. for Oleaceae (Fig. 5) (Damtoft
et al., 1992).
3.3. Fate of oleuropein
In the development of the olive fruit, three phases are usually
distinguished: a growth phase during which accumulation of
oleuropein occurs; a green maturation phase coinciding with
a reduction in the levels of chlorophyll and oleuropein; and
a black maturation phase characterised by the appearance of
anthocyanins and during which the oleuropein level continues
to fall (Amiot et al., 1989). Therefore oleuropein is very abun-
dant in the early stages: in young fruits it could reach 14% of
dry matter. Albeit lower, its level is still very important at har-
vest for green picked cultivars (Amiot et al., 1986). In the black
cultivars its level declines rapidly during maturation (Limiroli
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even fall to zero when they are completely black (Bianco
et al., 1993). Elenolic acid glucoside and demethyloleuropein,
glucosylated derivatives of oleuropein, appear at the beginning
of green maturation as the oleuropein levels decline. Then they
accumulate, reaching their maximum during black maturation,
until demethyloleuropein becomes the major constituent of
black olives (Bianco et al., 1993). It is possible that these two
compounds are formed from oleuropein by the action of ester-
ases, because esterase activity increased considerably during
the ﬁrst phase of maturation and reached a maximum during
black maturation (Amiot et al., 1989). The fruit O. europaea
appears to accumulate only glucosylated derivatives of oleu-
ropein. In contrast, dihydroxytyrosol and non-glucosylated
secoiridoids derived from oleuropein were found in the leaf
(Amiot et al., 1989, 1990).
The decline in oleuropein also coincided with the decline in
other quantitatively less important oleosides such as ligustro-
side and the increase in other phenolic compounds such as cer-
tain ﬂavonoids and verbascoside (Amiot et al., 1989). In young
small olives, verbascoside is present only in traces, while ligu-
stroside and cornoside are relatively abundant. When greenolives reach normal size, the ligustroside disappears and the
cornoside follows the same trend as the other compounds,
being easily transformed into halleridone (Bianco et al., 1993).
Considerable differences in the content of tyrosol, hydroxy-
tyrosol and tyrosol glucoside were also found to occur in the
fruits during growth and ripening of the drupe (Angerosa
et al., 1995; Limiroli et al., 1996), the increase in their levels
consistently correlating with the hydrolysis of the components
with higher molecular weight (Climato et al., 1990). The elen-
olic acid glucoside and hydroxytyrosol contents could be con-
sidered to be indicators for the maturation of olives (Esti et al.,
1998). Because of its interaction with a diphenol oxidase (PPO;
EC 1.10.3.2), oleuropein is also involved in the browning that
occurs in green table olives either after impact and wounding
during harvesting or during subsequent technological treat-
ments. Initially, this PPO is associated with the chloroplast
membranes, becoming increasingly soluble during maturation.
Therefore the degree of browning varies considerably
depending on the physiological stage of the fruit. The brown-
ing was found to be correlated to the oleuropein content and
not with PPO activity, indicating that endogenous substrates
are the main limiting factor (Goupy et al., 1991).
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116 S.H. Omar4. Bioavailability of oleuropein
Phenolic compounds from virgin olive oil have been demon-
strated to be highly bioavailable. Vissers et al. found that
absorption of administered ligistroside-aglycone, hydroxytyro-sol, tyrosol and oleuropein-aglycone was 55–60% in human
subjects (Vissers et al., 2002). They also suggested that an
important step in the metabolism of olive oil phenolics oleu-
ropein-glycoside ad oleuropein and ligistroside-aglycones is
their formation into hydroxytyrosol or tyrosol (Vissers et al.,
Figure 6 Proposed model for the action mechanisms of oleic acid and minor compounds from olive oil based on the literature gathered
for the present review. Despite the number of studies contributing to this model, several gaps that should be ﬁlled with further
investigation are still present. The main mechanism by which the components of olive oil inﬂuence endothelial activation involves
inhibition and/or scavenging of ROS. Oleic acid, oleuropein and b-sitosterol may reduce intracellular ROS by creating a less-oxidant
environment through inhibition of intracellular ROS production. b-Sitosterol may also enhance SOD activity, hence decreasing O2 levels.
This reduction has also been observed for the terpenoid oleanolic acid, although the mechanism is not presently known. Tocopherols and
phenolic compounds are potent antioxidants that may help reduce lipid peroxidation and scavenge intracellular ROS and free NO,
reducing the formation of OONO. ROS can activate the NFjB, which is then translocated into the nucleus, where it binds to recognition
sequences in DNA to induce gene expression. This mobilization of NFjB is blocked by a-tocopheryl succinate but not by a-tocopherol. In
contrast, phenolic compounds have been proposed to act blocking the formation of NFjB/DNA binding complexes. NFjB modulates the
expression of cytokines, LOX and COX, thereby affecting the levels of adhesion molecules and eicosanoids. However, some of the minor
compounds of olive oil may act directly on these enzymes and cytokines. LOX and COX activities are inhibited at different points by
phenolics and triterpenoids whereas IL-1b expression is inhibited by phenolics and tocopherols, contributing to protect the endothelium
against vasoconstriction, platelet aggregation and monocyte adhesion. Vasodilation is also suggested to be enhanced by oleuropein and
oleanolic acid through an increase in the production of NO.
Cardioprotective and neuroprotective roles of oleuropein in olive 1172002). It was supported by their ﬁnding that 15% of an oleu-
ropein-glycoside supplement administered to healthy human
subjects was excreted in urine as hydroxytyrosol and tyrosol
(Vissers et al., 2002). Another two studies showed that
oleuropein is rapidly absorbed after oral administration, with
maximum plasma concentration occurring 2 h after adminis-
tration. Hydroxytyrosol was its most important metabolite.
Both compounds are rapidly distributed and excreted in urine
mainly as glucoronides or in very low concentrations as free
forms (Tan et al., 2003; Boccio et al., 2003). Furthermore,
the mechanism of absorption of olive oil phenolics remains
unclear.
5. Cardioprotective effect of oleuropein
Epidemiological studies have shown that regular consumption
of phenol-rich foods is inversely associated with cardiovascular
disease (Stoclet et al., 2004). Oleuropein has a beneﬁcial effect
on several aspects of cardiovascular disease via its vasodilato-
ry, anti-platelet aggregation, anti-inﬂammatory and antioxi-
dant properties. A graphic summary of the mechanisms of
olive oil constituents is shown in Fig. 6.5.1. Antioxidant activity
Visioli and Galli reported that oleuropein effectively inhibited
CuSO4-induced LDL oxidation and proposing a link between
the Mediterranean diets correlated with a lower incidence of
coronary heart disease (Visioli and Galli, 1994). In 2002 and
2006, Visioli et al. (2002, 2006) documented that the oleurop-
ein exert potent antioxidant activities, such as inhibition of
low density lipoproteins oxidation and free radical scaveng-
ing. It modiﬁes pathophysiological processes at cellular level
favorably, e.g. by inhibiting not only the production of super-
oxide anions and the respiratory burst of neutrophils, but also
platelet aggregation and the production of thromboxane and
leukotriene B4 by neutrophils. According to De la Puerta
et al. (2001), oleuropein has both the ability to scavenge nitric
oxide and to cause an increase in the inducible nitric oxide
synthase (iNOS) expression in the cell. A scavenging effect
of oleuropein was demonstrated with respect to hypochlorous
acid (HOCl) (Visioli et al., 2002). HOCl is an oxidative sub-
stance produced in vivo by neutrophil myeloperoxidase at
the site of inﬂammation and can cause damage to proteins
including enzymes.
118 S.H. OmarConi and his research team (Coni et al., 2000) who found
that the addition of 10% (wt:wt) extra-virgin olive oil and
7 mg/kg oleuropein to the standard diet reduces plasma levels
of total cholesterol and increases the ability of LDL to resist
oxidation in the rabbits. The antioxidant potential of aqueous
oleuropein has been investigated in the isolated rat heart by
Manna et al. (2004). Male Sprague–Dawley (250–300 g) rats
were heparinised and anesthetized with thiopental by intraperi-
toneal injection. The hearts were excised and perfused in the
retrograde Langendorff mode under constant ﬂow. The organs
were subjected to 30 min of no-ﬂow global ischemia and then
reperfused. The protective effect of aqueous oleuropein
(20 lg/g) against the postischemic oxidative burst was investi-
gated by measuring the release, in the coronary efﬂuent, of the
oxidized glutathione, a sensitive marker of heart’s exposure to
oxidative stress. Reﬂow in ischemic hearts was accompanied
by a prompt release of oxidized glutathione; in ischemic hearts
pretreated with oleuropein, this release was signiﬁcantly re-
duced (Manna et al., 2004). De la Puerta et al. (1999) deter-
mined the anti-eicosanoid and antioxidant effects in
leukocytes of the principal phenolic compounds (oleuropein,
tyrosol, hydroxytyrosol and caffeic acid) from the polar frac-
tion of non-reﬁned olive oil.
Visioli et al. (2000) demonstrated that the administration of
catecholic phenolic compounds from olive oil, oleuropein, de-
crease, in a dose-dependent manner, the urinary excretion of 8-
iso-PGF2a, indicating lower in vivo lipid peroxidation pro-
cesses in supplemented volunteers. In 2006, Andreadou et al.
(2006) treatment with oleuropein for 6 wk reduced total cho-
lesterol and triglyceride concentrations along with reduction
of the infarct size, conferred strong antioxidant protection
and reduced the circulating lipids. This is the ﬁrst experimental
study in vivo that suggests the possibility of using an olive con-
stituent in the treatment of ischemia.
5.2. Anti-inﬂammatory effect
Visioli et al. (1998) showed that oleuropein increase nitric
oxide (NO) production in macrophages challenged with lipo-
polysaccharide, through an induction of the inducible form
of the enzyme nitric oxide synthase, thus increasing the func-
tional activity of these immunocompetent cells. It is well
known that oleuropein elicits anti-inﬂammatory effects by
inhibiting the lipoxygenase activity and the production of leu-
cotrien B4 (De la Puerta et al., 1999).
5.3. Anti-atherogenic effect
In terms of protection from atherosclerosis, the formation of
chloramines via the myeloperoxidase-catalyzed formation of
hypochloric acid and the subsequent chlorination of apolipo-
protein (apo)B-100 has been identiﬁed as one of the initiating
agents in LDL modiﬁcation, which leads to uncontrolled up-
take by macrophages. Visioli and Galli (2001) reported that
oleuropein showed anti-atherogenic activity through the
assessment of various markers, such as a reduced formation
of short-chain aldehydes (evaluated as thiobarbituric acid-
reacting substances [TBARS]) and of lipid peroxides, by a
higher vitamin E content in the residual LDL (indicating spar-
ing of endogenous antioxidants), and by a reduced formation
of malondialdehydelysine and 4-hydroxynonenal-lysine ad-
ducts, indicating protection of the apoprotein layer. Carluccioet al. (2003) reported that oleuropein reduces monocytoid cell
adhesion to stimulated endothelium, as well as vascular cell
adhesion molecule-1 (VCAM-1) mRNA and protein, which
is an essential early steps in atherogenesis. Manna et al. (2004)
showed the potential protective effects of oleuropein, in the iso-
lated rat heart pretreatment with 20 lg/g oleuropein against the
post-ischemic oxidative burst in the coronary efﬂuent and the re-
lease of oxidized glutathione, a sensitive marker of heart’s expo-
sure to oxidative stress and a key factor in the pathogenesis of
atherosclerosis. The extent of lipid peroxidation was evaluated
by measuring thiobarbituric acid-reactive substance concentra-
tion in the muscle (Manna et al., 2004). The anti-atherosclerotic
effect of aqueous olive leaf extract was also demonstrated in rab-
bits on a high-lipid diet. Twenty-four rabbits were assigned to
control, high-lipid diet, or high-lipid diet supplemented with
(OLE) aqueous olive leaves extract (contains oleuropein) for
6 weeks. Animals in the high-lipid diet group had higher levels
of cholesterol, triglycerides and LDL cholesterol, as well as a
thick layer of lipid disposition in the aortic intima compared
to those in the OLE group. These results support olive leaf’s
anti-atherosclerotic effect, most likely related to suppression
of inﬂammation (Wang et al., 2008).
5.4. Anti-hypertensive effect
Animal studies demonstrated that the aqueous and ethanolic ol-
ive leaves extract (OLE) given to hypertensive rats at dosages
ranging from 100 to 1000 mg/kg for 2–6 weeks signiﬁcantly low-
ered mean arterial pressure and heart rate (Osim et al., 1999;
Khayyal et al., 2002). Another animal study showedmethanolic
OLE (consists oleuropein) given to salt-sensitive, genetically
hypertensive rats at 60 mg/kg body weight for 6 weeks pre-
vented the development of severe hypertension and atheroscle-
rosis and improved insulin resistance (Somova et al., 2003).
In a human clinical trial ethanolic OLE reduced blood pres-
sure in 40 borderline hypertensive pairs of monozygotic twins.
Twins from each pair were assigned to control or two treat-
ment groups receiving either 500 or 1000 mg OLE daily for
8 weeks. Body weight, heart rate, blood pressure, glucose
and lipids were measured at 2-week intervals. Blood pressure
values decreased within pairs, with an average difference in
systolic pressure up to 6 mmHg between the 500-mg OLE
group and control group and up to 13 mmHg difference be-
tween 500- and 1000-mg groups after 6 weeks; maximum dif-
ferences in diastolic blood pressure in the same two groups
were 5 mmHg in each. At the end of the study, mean blood
pressure remained unchanged for those in the control and
500-mg groups, while those in the 1000-mg group reported a
signiﬁcant decrease in mean systolic blood pressure
(137 ± 10 to 126 ± 6; p< 0.01). All subjects reported de-
creases in cholesterol, with no signiﬁcant changes in other
parameters (Perrinjaquet-Moccetti et al., 2008). Another clini-
cal trial (n= 30) reported signiﬁcant decreases in blood pres-
sure in hypertensive patients given 400 mg aqueous OLE
four times daily for 3 months. Full text of the study was
unavailable and published in French and actual percentage de-
crease was not reported in the abstract (Cherif et al., 1996).
5.5. Anti-platelet aggregation
Petroni et al. (1995) reported that components of the phenolic
fraction of olive oil in vitro inhibit platelet function and
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Figure 7 Diagramic representation of the neuroprotective role of
oleuropein.
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tetraenoic acid (12-HETE). Olive leaf polyphenols have been
shown to inhibit in vitro platelet function in blood obtained
from 11 healthy, non-smoking males. Olive leaf polyphenols
(at increasing concentrations of oleuropein) effected a signiﬁ-
cant dose-dependent suppression of platelet-ATP release and
platelet aggregation (Singh et al., 2008). Recently Dell’Agli
et al. (2008) reported that olive oil phenols (oleuropein-agly-
cone) inhibit platelet aggregation via cAMP-PDE inhibition
mechanism in the venous blood sample of the healthy volun-
teers; one of the targets of the biological effect.
5.6. Oleuropein protectant activity against doxorubicin induced
cardiotoxicity
Adriamycin (doxorubicin (DXR)) is a commonly used anti-
neoplastic agent, but its use is mainly limited by the occurrence
of dose-dependent cardiotoxicity Cole et al., 2006. It also in-
duces hepatotoxic (Kwiecien et al., 2006) and neurotoxic (Joshi
et al., 2007) effects. Andreadou et al. (2007) demonstrated that
oleuropein successfully treats DXR-induced cardiotoxicity by
inhibiting lipid peroxidation products, decreasing oxidative
stress and reducing nitric oxide synthase (iNOS) in cardiomyo-
cytes. Recently, Andreadou et al. (2009) showed that oleurop-
ein completely restored the changes of metabolites to the
normal levels. Acetate and succinate constitute novel biomark-
ers related to DXR, and oleuropein treatment aids the com-
pensation of distressed energy metabolic pathways.
6. Neuroprotective effect
According to the free radical theory, ageing is the result of the
oxidative injury, mainly to mitochondria, throughout the life-
time. Some of the oxidative damages can not entirely be coun-
teracted and lead to cellular dysfunction. Mitochondrial
membranes are very sensitive to free radical attack because
of the presence of double bond carbon-carbon in the lipid tails
of its phospholipids, which leads to the production of cognitive
and neurodegenerative disease. In vitro (Moosmann and Behl,
1999) and epidemiological (German and Walzem, 2000) stud-
ies pointed out the positive impact of natural extracted poly-
phenols on the incidence of age-related disorders, such as
dementia. In a study (Panza et al., 2004) reported that oleurop-
ein, was evaluated towards the decrease or even prevention of
Ab aggregation, which is inherent to Alzheimer’s disease (AD).
The potential effect of oleuropein on the brain function has
been reported that AD is analogous to atherosclerosis, because
they both are age-dependent diseases in which abnormal accu-
mulation of a normal metabolite (cholesterol and Ab, respec-
tively) precedes clinical symptoms and leads to disease
(Golde and Eckman, 2001; Hofman et al., 1997). The link
between heart disease, hypercholesterolemia and AD (Refolo
et al., 2000) involve similar mechanisms in the pathogenesis
of these disorders. The circumstantial evidence that choles-
terol-related interventions can alter Ab deposition (Refolo
et al., 2001; Jick et al., 2000), suggest that oleuropein could
be promising in the management of AD. Furthermore, the
importance of inﬂammatory processes in the clinical manifes-
tation of AD (Markesbery and Carney, 1999; Heininger,
1999), combined with the epidemiological evidence of a protec-
tive effect of anti-inﬂammatory agents (Stewart et al., 1997)
against AD, suggest that a polyphenolic natural extract, suchas oleuropein, could prove effective against age dependent.
The diagrammatic representation of the neuroprotective role
of oleuropein is shown in Fig. 7.
7. Conclusion
The traditional Mediterranean diet contains, unlike the North-
ern European and American diet, a considerable proportion of
vegetables, cereals, fruit, ﬁsh, milk, wine and olive oil. The
beneﬁcial effects of olive oil are attributed to a favorable fatty
acid proﬁle and to the presence of some minor components
that are also responsible for its unique ﬂavour and taste. The
major constituent of the leaves, virgin olive oil and unpro-
cessed olive drupes of O. europaea is oleuropein. There are a
number of researches documented on the cardioprotective role
of oleuropein and their possible therapeutic tools for pharma-
cological treatment of CHD. But still very few studies reported
that the relation of oleuropein and neuroprotection viz.
anti-Parkinsonism’s action and dementia and schizophrenia.
There is further need of research to investigate the neuropro-
tective role of oleuropein and its relation with cardiovascular
disease.
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